

SYNTHESIS OF PHOSPHONATE ANALOGUES OF MYO-INOSITOL PHOSPHOLIPIDS

C.E. Dreef, C.J.J. Elie, G.A. van der Marel and J.H. van Boom

Gorlaeus Laboratories, P.O. Box 9502, 2300 RA Leiden, The Netherlands


ABSTRACT. The phosphonate analogues **I** and **II** of PtdIns and PtdIns[4]P, respectively, were prepared by alkylation of the α -lithio anion of a properly protected *D*-myo-inositol methylphosphonate diester with 1,2-isopropylidene-*sn*-glycerol 3-trifluoromethanesulfonate, followed by protective group manipulation and deprotection

It is now well established that cleavage of phosphatidylinositol 4,5-bisphosphate (PtdIns[4,5]P₂) by receptor mediated phospholipase C upon stimulation by neurotransmitters, hormones and growth factors¹, results in the formation of two second messengers *e.g.* *D*-myo-inositol 1,4,5-trisphosphate² and 1,2-diacylglycerol³. The supply of PtdIns[4,5]P₂ is constantly replenished by sequential phosphorylation of phosphatidylinositol (PtdIns)⁴. Initially, PtdIns is phosphorylated by a specific PtdIns 4-kinase to give phosphatidylinositol 4-phosphate (PtdIns[4]P), which in turn is phosphorylated by a PtdIns[4]P 5-kinase to generate the key lipid PtdIns[4,5]P₂.

Since the pioneering work of Shvets and others⁵, the synthesis of inositol phospholipids and analogues thereof has received renewed attention⁶. For instance, phosphorothioate analogues of PtdIns have been prepared⁷ and applied to determine the stereochemical course of the cleavage reaction by PtdIns-specific phospholipase C.

Apart from this, it has been shown⁸ that phosphonate analogues of PtdIns are effective phospholipase C inhibitors. For example, the phosphonate analogue **I** (see Figure) proved to be a potent anti-inflammatory and analgesic agent. The racemic isosteric analogue **I** of PtdIns was prepared⁸ by trichloroacetonitrile-mediated condensation of 2,3,4,5,6-penta-*O*-benzyl-*myo*-inositol⁹ with 3,4-dipalmitoyloxybutyl-1-phosphonic acid¹⁰, followed by removal of all benzyl protecting groups. As part of a programme directed towards the preparation of *myo*-inositol phospholipids and phosphate analogues thereof, we now describe a versatile approach towards the synthesis of the optically active phosphonate analogues **I** and **II** of PtdIns and PtdIns[4]P, respectively.


Figure



The synthesis of the phosphonate analogues **I** and **II** comprises three main stages, (a) the preparation of a suitably protected *D*-myo-inositol derivative, (b) the introduction of the optically active phosphotidic acid and finally the removal of all protecting groups.

In the first stage, 1,2,4,5-di-*O*-cyclohexylidene inositol (**1**)¹¹ was converted into the properly protected *D*-myo-inositol derivative **8** as depicted in Scheme 1. Thus, compound **1** was regioselectively allylated with allyl bromide in the presence of BaO/Ba(OH)₂ in DMF¹² for 72 h at 20°C to afford, after work-up and purification, the crystalline mono-allyl derivative **2**¹³ (mp. 116.5-117.5°C) in a yield of 68%. Subsequent *p*-methoxybenzylation (*p*MeOBzCl/NaH) of **2**, followed by selective removal of the 4,5-cyclohexylidene group (0.1M HOCH₂CH₂OH in CH₂Cl₂) from **3** gave, after

Scheme 1




column chromatography, compound **4** (mp 142–143°C) in a yield of 71%. After benzylation (BzlBr/NaH) of **4**, the 1,2-*cis*-cyclohexylidene group from **5** was removed by treatment with 0.05N HCl in MeOH to give crystalline **6** (mp 112.5–113.5°C) in 89% yield. Benzylation (BzlBr/NaH) of compound **6** furnished the fully protected *myo*-inositol **7** in a yield of 98%. Isomerization¹⁴ of the allyl group in **7** with 1,5-cyclooctadiene-*bis*[methyl(diphenyl)phosphine]-iridium hexafluorophosphate¹⁵ (activated with H₂ for 2 min) in 1,2-dichloroethane, followed by hydrolysis of the intermediate *trans*-prop-1-enyl group with 0.1N HCl in CH₂Cl₂/MeOH (1/1, v/v), resulted in the isolation of the racemic 1-OH-derivative **8** (mp 69.5–70.5°C) in 95% yield. Optical resolution of the alcohol **8** could be realized by converting it with (–)-camphoric acid chloride into the corresponding diastereomeric camphanate esters **9**¹⁶. Separation of these diastereomers by silica gel column chromatography gave **9L** (46% yield, mp 141–141.5°C, $[\alpha]_D^{20} +13.3^\circ$, c 1, CHCl₃) and **9D** (43% yield, mp. 152.5–153.5°C, $[\alpha]_D^{20} -18.8^\circ$, c 1, CHCl₃) in greater than 98% diastereomeric excess, as gauged by ¹H-NMR spectroscopy. Hydrolysis with 0.2N NaOH in dioxane/MeOH/H₂O (14/5/1, v/v/v) of the camphanate-ester groups of the individual diastereomers afforded the enantiomers **8L**¹⁷ (mp 73.5–74.5°C, $[\alpha]_D^{20} +12.2^\circ$, c 1, CHCl₃) and **8D** (mp 73.5–74.5°C, $[\alpha]_D^{20} -12.2^\circ$, c 1, CHCl₃) in 98% and 99% yield, respectively.

The next stage in the synthesis of the phosphonate analogues **I** and **II** of PtdIns and PtdIns[4]P consisted (see Scheme 2) of the introduction of the phosphotidic acid function¹⁸. In the first step, the alcohol **8D** was reacted with a slight excess of the new bifunctional phosphorylating agent *bis*(1-[6-trifluoromethyl]benzotriazolyl)methylphosphonate¹⁹ (1.1 eq) in dioxane for 15 min at 20°C to give the putative (1-[6-trifluoromethyl]benzotriazolyl)methylphosphonate intermediate. *In situ* treatment of the latter with benzyl alcohol (2 eq) in the presence of *N*-methylimidazole (5 eq) gave, after 1 h at 20°C, the methylphosphonate **10** (diastereomeric mixture, ratio 1/3; δ_p 31.07 and 32.88 ppm) in an overall yield of 90%. Treatment of the α -lithio methylphosphonate, prepared from one diastereomer of the methylphosphonate **10**²⁰ (1 mmol) and butyllithium (1 mmol) in THF (10 ml) at –78°C, with 1,2-isopropylidene-*sn*-glycerol 3-trifluoromethanesulfonate **11**²¹ (1.05 mmol) at –40°C for 1 h, yielded after work-up and purification, derivative **12**. Hydrolysis of the isopropylidene function of **12** with 0.05N HCl in MeOH gave, after work-up and purification, diol **13** (δ_p 35.36 ppm) in 45% overall yield. Acylation of **13** with palmitoyl chloride (2 eq) and pyridine (2 eq) in CH₂Cl₂ for 2 h at 35°C furnished the fully protected *myo*-inositol phospholipid analogue **14** (δ_p 33.00 ppm) in 84% yield. Cleavage of the *p*-methoxybenzyl group with 2.5% CF₃COOH in CH₂Cl₂ gave the 4-OH-derivative **15** (δ_p 33.12 ppm) in a yield of 86%. Finally, hydrogenolysis (H₂/Pd(OH)₂/(EtOAc/EtOH/H₂O=70/25/5, v/v/v)) of compound **15** under pressure for 16 h gave **I**²², which was isolated as the homogeneous ammonium-salt.

On the other hand, phosphorylation of compound **15** with *N,N*-diisopropyl dibenzyl phosphoramidite²³, in the presence of 1*H*-tetrazole, followed by oxidation of the intermediate phosphite-triester with *t*-BuOOH²⁴, afforded the fully protected *myo*-inositol phospholipid analogue **16** (δ_p –0.91 and 33.15 ppm) in a yield of 85%. Deprotection of compound **16**, as described above, furnished the ammonium-salt of **II**²².

Scheme 2




The results presented in this paper nicely illustrate the usefulness of the protected methylphosphonate derivative **10**. Thus, the corresponding α -lithio anion of **10** could be readily alkylated to give an easy access to the phosphonate analogues I and II, which are valuable tools to study in detail the inhibition of phospholipase C. Furthermore, we believe that the approach described herein promises to be of great value for the future synthesis of other isosteric phosphonate analogues of naturally occurring phosphate esters.

REFERENCES AND NOTES

- 1 C.P. Downes and R.H. Michell in "Molecular Mechanisms of Transmembrane Signalling", eds P. Cohen and M.D. Houslay, Elsevier, Amsterdam, 1985, p. 3
- 2 M.J. Berridge and R.F. Irvine, *Nature*, **312**, 315 (1984)
- 3 Y. Nishizuka, *Nature*, **308**, 693 (1984)
- 4 C.P. Downes and C.H. Macphée, *Eur. J. Biochem.*, **193**, 1 (1990)
- 5 a. A.E. Stepanov and V.I. Shvets, *Chem. Phys. Lipids*, **25**, 247 (1979), b. R. Gigg, *Chem. Phys. Lipids*, **26**, 287 (1980)
- 6 a. J.G. Ward and R.C. Young, *Tetrahedron Lett.*, **29**, 6013 (1988); b. C.E. Dreef, C.J.J. Elie, P. Hoogerhout, G.A. van der Marel and J.H. van Boom, *Tetrahedron Lett.*, **29**, 6513 (1988); c. M. Jones, K.K. Rana, J.G. Ward and R.C. Young, *Tetrahedron Lett.*, **30**, 5353 (1989); d. R.C. Young, C.P. Downes, D.S. Eggleston, M. Jones, C.H. Macphée, K.K. Rana and J.G. Ward, *J. Med. Chem.*, **33**, 641 (1990)
- 7 a. G. Lin and M.-D. Tsai, *J. Am. Chem. Soc.*, **111**, 3099 (1989); b. G. Lin, C.F. Bennett and M.-D. Tsai, *Biochemistry*, **29**, 2747 (1990); c. G.M. Salamonczyk and K.S. Bruzik, *Tetrahedron Lett.*, **31**, 2015 (1990)
- 8 S.S. Yang, T.R. Beattie, P.L. Durette, T.F. Gallagher and T.-Y. Shen, *US Pat.* 4,515,722 (1985)
- 9 R. Gigg and C.D. Warren, *J. Chem. Soc. (C)*, 2367 (1969)
- 10 J.-C. Tang, B.E. Tropp, R. Engel and A.F. Rosenthal, *Chem. Phys. Lipids*, **17**, 169 (1976)
- 11 a. P.J. Garegg, T. Iversen, R. Johansson and B. Lindberg, *Carbohydr. Res.*, **130**, 322 (1984); b. C.E. Dreef, G.A. van der Marel and J.H. van Boom, *Recl. Trav. Chim. Pays-Bas*, **106**, 161 (1987)
- 12 C.J.J. Elie, R. Verduyn, C.E. Dreef, D.M. Brounts, G.A. van der Marel and J.H. van Boom, *Tetrahedron*, **46**, 8243 (1990)
- 13 All new compounds were characterized by ¹H- and ¹³C-NMR as well as by combustion analysis.

- 14 J.J. Oltvoort, C.A.A. van Boeckel, J.H. de Koning and J.H. van Boom, *Synthesis*, 305 (1981)
 15 L.M. Haines and E. Singleton, *J. Chem. Soc. Dalton Trans.*, 1891 (1972).
 16 D.C. Billington, R. Baker, J.J. Kulagowski and I.M. Mawer, *J. Chem. Soc., Chem. Commun.*, 314 (1987).
 17 The absolute configuration of **8L** was confirmed by its transformation into 2,3,4,5,6-penta-*O*-benzyl-L-*myo*-inositol and comparison of the observed $[\alpha]_D^{25}$ -value (+8.8°, c 1, CHCl₃) with the reported⁹ one (+9.2°, c 3.25, CHCl₃)



- 18 In a preliminary experiment it was found that alkylation of the α -lithio anion of dibenzyl methylphosphonate with triflate **11** afforded, after hydrolysis of the isopropylidene function, subsequent palmitoylation and hydrogenolysis, the corresponding phosphonate analogue of phosphatidic acid in an overall yield of 35%.
- 19 *Bis*(1-[6-trifluoromethyl]benzotriazolyl)methylphosphonate was prepared by dropwise addition of commercially available methylphosphonic dichloride (5 mmol) in dioxane (5 ml) to a cooled solution (0°C) of 1-hydroxy-6-trifluoromethylbenzotriazole (10 mmol) and pyridine (10 mmol) in dioxane (20 ml). After stirring for 1 h at 20°C, the salts were removed by filtration. The thus obtained 0.2M stock solution of (CF₃BtO)₂P(O)CH₃ could be stored for several weeks at -20°C.
- 20 Separation of the individual diastereomeric methylphosphonate diesters **10** could be accomplished by silica gel column chromatography (elution, *n*-hexane/ethyl acetate, 1/0 to 1/1, v/v). Only the lower-running diastereomer was used to facilitate the interpretation of the ¹H- and ¹³C-NMR spectra.
- 21 The triflate **11** was prepared starting from commercially available 1,2-isopropylidene-*sn*-glycerol (R.W. Binkley, M.G. Ambrose and D.G. Hehemann, *J. Org. Chem.* **45**, 4387 (1980)).
- 22 Compound I: ³¹P-NMR (CH₂Cl₂/CH₃OH/H₂O, 70/30/3, v/v/v) δ 27.56 ppm. ¹H-NMR (CDCl₃/CD₃OD/D₂O, 70/30/3, v/v/v) δ 0.88 (t, 6 H, 2 x CH₃, palmitoyl, J = 7.0 Hz), 1.20-1.46 (m, 48 H, 24 x CH₂, palmitoyl), 1.54-1.78 and 1.82-1.95 (m, 8 H, 2 x H-1 (butyl), 2 x H-2 (butyl) and 2 x C(=O)CH₂CH₂, palmitoyl), 2.30 (t, 2 H, C(=O)CH₂, palmitoyl, J = 7.5 Hz), 2.32 (t, 2 H, C(=O)CH₂, palmitoyl, J = 7.5 Hz), 3.25 (dd, 1 H, H-5 (inositol), J_{5,6} = 9.0 Hz), 3.46 (dd, 1 H, H-3 (inositol), J_{3,4} = 10.0 Hz), 3.63 (dd, 1 H, H-4 (inositol), J_{4,5} = 9.0 Hz), 3.74 (dd, 1 H, H-6 (inositol), J_{6,1} = 10.0 Hz), 4.03 (m, 1 H, H-1 (inositol), J_{1,2} = 2.5 Hz), 4.04 (dd, 1 H, H-4a (butyl), J_{4a,4b} = 12.0 Hz), 4.14 (dd, 1 H, H-2 (inositol), J_{2,3} = 2.5 Hz), 4.29 (dd, 1 H, H-4b (butyl), J_{4a,4b} = 12.0 Hz), 5.13 (m, 1 H, H-3 (butyl), J_{3,4a} = 3.0 Hz).
- Compound II: ³¹P-NMR (CH₂Cl₂/CH₃OH/H₂O, 70/30/3, v/v/v) δ 2.51 and 26.99 ppm. ¹H-NMR (CDCl₃/CD₃OD/D₂O, 70/30/3, v/v/v) δ 0.89 (t, 6 H, 2 x CH₃, palmitoyl, J = 7.0 Hz), 1.21-1.31 (m, 48 H, 24 x CH₂, palmitoyl), 1.52-1.80 and 1.83-1.97 (m, 8 H, 2 x H-1 (butyl), 2 x H-2 (butyl) and 2 x C(=O)CH₂CH₂, palmitoyl), 2.30 (t, 2 H, C(=O)CH₂, palmitoyl, J = 8.0 Hz), 2.33 (t, 2 H, C(=O)CH₂, palmitoyl, J = 8.0 Hz), 3.48 (br, 1 H, H-5 (inositol)), 3.67 (br, 1 H, H-3 (inositol)), 3.81 (br, 1 H, H-6 (inositol)), 4.00-4.25 (m, 2 H, H-1 (inositol) and H-2 (inositol)), 4.05 (dd, 1 H, H-4a (butyl), J_{4a,4b} = 12.0 Hz), 4.32 (dd, 1 H, H-4b (butyl), J_{4a,4b} = 12.0 Hz), 4.19 (br, 1 H, H-4 (inositol)), 5.13 (m, 1 H, H-3 (butyl), J_{3,4a} = 7.5 Hz, J_{3,4b} = 3.0 Hz).
- 23 a K.-L. Yu and B. Fraser-Reid, *Tetrahedron Lett.*, **29**, 979 (1988); b C.E. Dreef, R.J. Tuinman, C.J.J. Elie, G.A. van der Marel and J.H. van Boom, *Recl. Trav. Chim. Pays-Bas*, **107**, 395 (1988).
- 24 J. Engels and A. Jager, *Angew. Chem. Suppl.*, 2010 (1982).

ACKNOWLEDGEMENT

This investigation was supported by the Netherlands Organization for Scientific Research (NWO).

(Received in UK 14 December 1990)